Literature DB >> 12392892

Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts.

Gui-Rong Li1, Chu-Pak Lau, Alvin Shrier.   

Abstract

The different sodium channel currents (I(Na)) were reported in myocardium, neuron, and skeletal muscles. To study whether I(Na) is homogeneous within the heart, we applied whole-cell voltage clamp technique to evaluate fast voltage-gated I(Na) in atrial and ventricular myocytes isolated from guinea pig heart. It was found that the density of inward I(Na) was 50% greater at -35 mV in atrial (-42.6+/-2.9 pA/pF) than in ventricular (-27.5+/-1.8 pA/pF, P<0.01) myocytes. The half activation and inactivation voltages (V(0.5)) of I(Na) in atrial myocytes were shifted 4.5+/-0.2 and 9.6+/-0.3 mV negative to those of ventricular myocytes. Time constants for I(Na) activation (tau(m)) and inactivation (tau(h)) were twice as rapid in atrial as in ventricular myocytes. The tau(m) and tau(h) were 0.34+/-0.03 and 1.36+/-0.07 ms for atrial myocytes, and 0.69+/-0.05 and 3.27+/-0.23 ms for ventricular myocytes, respectively. Recovery of I(Na) from inactivation was slower in atrial than in ventricular myocytes, whereas the development of resting state inactivation was more rapid in atrial (tau=67.5+/-4.3 ms) than in ventricular (152.8+/-7.5 ms, P<0.01) myocytes. The results reveal marked heterogeneity of I(Na) in the density and biophysical properties in atrial and ventricular myocytes, and the study suggests the potential possibility of tissue specific cardiac sodium channel isoforms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392892     DOI: 10.1006/jmcc.2002.2053

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  32 in total

Review 1.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

Review 2.  Role of late sodium channel current block in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

3.  How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Atr Fibrillation       Date:  2008

4.  AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog.

Authors:  Alexander Burashnikov; Andrew C Zygmunt; Jose M Di Diego; Gunilla Linhardt; Leif Carlsson; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2010-07       Impact factor: 3.105

5.  Clemizole hydrochloride blocks cardiac potassium currents stably expressed in HEK 293 cells.

Authors:  Ling-Jun Jie; Wei-Yin Wu; Gang Li; Guo-Sheng Xiao; Shetuan Zhang; Gui-Rong Li; Yan Wang
Journal:  Br J Pharmacol       Date:  2017-01-12       Impact factor: 8.739

Review 6.  Atrial-selective sodium channel blockers: do they exist?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2008-08       Impact factor: 3.105

Review 7.  Atrial fibrillation and Brugada syndrome.

Authors:  Johnson Francis; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2008-03-25       Impact factor: 24.094

Review 8.  Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.

Authors:  Charles Antzelevitch; Alexander Burashnikov
Journal:  J Electrocardiol       Date:  2009-08-20       Impact factor: 1.438

9.  Genome-wide association study of electrocardiographic conduction measures in an isolated founder population: Kosrae.

Authors:  J Gustav Smith; Jennifer K Lowe; Sirisha Kovvali; Julian B Maller; Jacqueline Salit; Mark J Daly; Markus Stoffel; David M Altshuler; Jeffrey M Friedman; Jan L Breslow; Christopher Newton-Cheh
Journal:  Heart Rhythm       Date:  2009-02-15       Impact factor: 6.343

Review 10.  New pharmacological strategies for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.